Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators

J Med Chem. 2009 Nov 26;52(22):7186-91. doi: 10.1021/jm901149c.

Abstract

Herein we describe the discovery of ACP-105 (1), a novel and potent nonsteroidal selective androgen receptor modulator (SARM) with partial agonist activity relative to the natural androgen testosterone. Compound 1 was developed from a series of compounds found in a HTS screen using the receptor selection and amplification technology (R-SAT). In vivo, 1 improved anabolic parameters in a 2-week chronic study in castrated male rats. In addition to compound 1, a number of potent antiandrogens were discovered from the same series of compounds whereof one compound, 13, had antagonist activity at the AR T877A mutant involved in prostate cancer.

MeSH terms

  • Administration, Oral
  • Androgen Receptor Antagonists*
  • Androgens*
  • Animals
  • Azabicyclo Compounds / chemistry*
  • Azabicyclo Compounds / metabolism
  • Azabicyclo Compounds / pharmacokinetics
  • Azabicyclo Compounds / pharmacology*
  • Dogs
  • Drug Design
  • Humans
  • Ligands
  • Male
  • Mice
  • Microsomes, Liver / metabolism
  • Mutation
  • NIH 3T3 Cells
  • Orchiectomy
  • Prostatic Neoplasms / genetics
  • Rats
  • Receptors, Androgen / genetics
  • Receptors, Androgen / metabolism
  • Structure-Activity Relationship
  • Substrate Specificity
  • Testosterone Propionate / pharmacology

Substances

  • 2-chloro-4-(3-hydroxy-3-methyl-8-azabicyclo(3.2.1)oct-8-yl)-3-methylbenzonitrile
  • Androgen Receptor Antagonists
  • Androgens
  • Azabicyclo Compounds
  • Ligands
  • Receptors, Androgen
  • Testosterone Propionate